To investigate the potential alterations associated with response and/or resistance to endocrine therapy and/or PI3K inhibition in ER+, HER2− breast cancer tumours, we analysed baseline and end‐of‐treatment ctDNA collected from SANDPIPER participants. This evidence concerns the gene ERBB2 and breast carcinoma.